The future therapy of endometrial cancer: microRNA’s functionality, capability, and putative clinical application
详细信息 查看全文
- 作者：Matthias B. Stope ; Dominique Koensgen ; Jörg Weimer…
- 关键词：Endometrial cancer ; MicroRNA ; Diagnosis ; Prognosis ; Biomarker
- 刊名：Archives of Gynecology and Obstetrics
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：294
- 期：5
- 页码：889-895
- 全文大小：374 KB
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Gynecology
Obstetrics and Perinatology
Endocrinology
Human Genetics - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-0711
- 卷排序：294
文摘
PurposeEndometrial cancer (EC) therapy is characterized by the heterogeneity of EC subtypes resulting in unclear clinical behavior as well as in unsatisfactory treatment options. The available biomarkers, such as cellular tumor antigen p53 (TP53), phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase (PTEN), and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) genes alone might not be sufficient, and thus, new predictive and prognostic biomarkers are urgently required. The biomolecule class of microRNA represents a group of endogenously expressed regulatory factors primarily involved in control of pivotal cancer-related mechanisms including cell cycle, proliferation, apoptosis, and metastasis. Here, we review the current state of science regarding microRNA functionality in EC progression.